A pharmaceutical-grade version of LSD — taken as a dissolving tablet — significantly eased anxiety in a large late-stage trial, the latest sign that psychedelics are edging toward mainstream medicine.
Definium Therapeutics’ drug, DT120, is an orally disintegrating tablet delivering a controlled dose of LSD. In its Phase 3 “Voyage” study in generalized anxiety disorder (GAD), announced August 12, 2026, patients’ anxiety scores (on a 56-point scale) fell by an average of 11.6 points 12 weeks after dosing — a 5.4-point separation from placebo that beat Wall Street’s expectations. Effects were seen as early as day two, and treatment sessions lasted about 6.4 hours on average.
Safety and reaction
The company reported no new safety concerns and no signals of suicidal thoughts or behaviors. Investors approved: Definium’s shares rose about 15% at the open. One analyst, Leerink’s Marc Goodman, called the data “about as good as we could have hoped for.”
Why it matters
The result builds on positive Phase 3 depression data Definium reported in June, and analysts project multibillion-dollar peak sales across anxiety, depression and PTSD if approvals follow. Psychedelic medicines remain investigational and are given under close supervision, not self-administered — but a second strong Phase 3 readout strengthens the case that a carefully dosed LSD pill could become a real treatment option.
This article describes an investigational drug and clinical-trial results, and is not medical advice. Psychedelics are studied under medical supervision; do not attempt self-treatment.